Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second qua

Setbacks for competitors have positioned ResMed to capture more market share.

AI regulation odds have sharply declined after Trump dismissed AI takeover concerns during a public

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

RMD's software portfolio optimization, mask innovation and solid financial health support growth, th

RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform a

Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold move

ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rathe

A Qualified Charitable Distribution can wipe your RMD off your tax return entirely, but it also kill

Hsbc Holdings PLC grew its position in shares of ResMed Inc. (NYSE: RMD) by 13.4% during the second

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price

Canada Pension Plan Investment Board bought a new stake in shares of ResMed Inc. (NYSE: RMD) in the

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farre

American Capital Management Inc. bought a new stake in shares of ResMed Inc. (NYSE: RMD) in the unde

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Turning 73 changes the math on your retirement account. The IRS no longer lets your traditional IRA

Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutra

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health techno

Avalon Trust Co bought a new stake in ResMed Inc. (NYSE: RMD) during the undefined quarter, accordin

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises t

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price

Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers th

US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after wea

ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus es

Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price

Wall Street analysts change outlook on top names. Complete view of analyst rating changes including

Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the

Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price tar

ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh ne

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and lowers the p

Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers th

On July 7, 2026, ResMed Inc. (the "Company" or "Resmed") issued a press release anno

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and

Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the pri

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrad

Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J

Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight

Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in compani

Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the p

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and

ResMed (NYSE:RMD) reported quarterly earnings of $2.86 per share which beat the analyst consensus es